|
|
Volumn 103, Issue 23, 2011, Pages 1730-1731
|
|
Large-scale genome projects enter the clinic on both sides of the Atlantic.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR;
PHOSPHATIDYLINOSITOL 3 KINASE;
PIK3CA PROTEIN, HUMAN;
TUMOR MARKER;
CANCER CENTER;
DNA SEQUENCE;
DRUG INDUSTRY;
GENETIC SCREENING;
GENETICS;
GENOTYPE;
HUMAN;
HUMAN GENOME;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MUTATION;
NEOPLASM;
NETHERLANDS;
NOTE;
PUBLIC HEALTH;
UNITED KINGDOM;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CANCER CARE FACILITIES;
DRUG INDUSTRY;
GENETIC TESTING;
GENOME, HUMAN;
GENOTYPE;
GREAT BRITAIN;
HUMANS;
MOLECULAR TARGETED THERAPY;
MUTATION;
NATIONAL HEALTH PROGRAMS;
NEOPLASMS;
NETHERLANDS;
PHOSPHATIDYLINOSITOL 3-KINASES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SEQUENCE ANALYSIS, DNA;
TUMOR MARKERS, BIOLOGICAL;
UNITED STATES;
|
|
EID: 84856256904
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr503 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
